Ruth Flumann
Koeln, NW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Non-ICANS neurotoxicity after BCMA-directed CAR-T therapy: Clinical spectrum, outcomes, and a framework for neurology-oncology co-management.
Journal: HemaSphere
Published: March 15, 2026
Effectiveness of an on-site vaccination campaign for patients with cancer.
Journal: BMC public health
Published: March 05, 2026
Expression of cFLIP in B cells is essential for diffuse large B-cell lymphoma pathogenesis.
Journal: Blood
Published: January 21, 2026
Sequential BCMA CAR T-cell therapy in refractory multiple myeloma.
Journal: Blood advances
Published: April 01, 2025
CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma.
Journal: Cancer cell
Published: August 25, 2024
Noninvasive minimal residual disease assessment in relapsed/refractory large B-cell lymphoma using digital droplet PCR.
Journal: European journal of haematology
Published: December 30, 2023
Mouse models of diffuse large B cell lymphoma.
Journal: Frontiers in immunology
Published: October 10, 2023
An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80/86-upregulated DLBCL.
Journal: Cell reports. Medicine
Published: September 22, 2022
An Aged/Autoimmune B-cell Program Defines the Early Transformation of Extranodal Lymphomas.
Journal: Cancer discovery
Published: May 13, 2022
Distinct Genetically Determined Origins of Myd88/BCL2-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies.
Journal: Blood cancer discovery
Published: January 20, 2022
Last Updated: 09/26/2026